Comparative evaluation of sputum microscopy and Xpert MTB/RIF assay for tuberculosis detection and rifampicin resistance surveillance in Biratnagar, Nepal

Tuberculosis (TB) control in Nepal faces persistent challenges due to underdiagnosis and increasing drug resistance. This study assessed the diagnostic performance of the Xpert MTB/RIF assay compared with conventional smear microscopy and estimated the prevalence of rifampicin-resistant TB (RR-TB) in Biratnagar, a high-burden urban center. Between March and September 2023, 509 clinical specimens from TB suspects were analyzed by Ziehl-Neelsen (ZN) staining, fluorescence microscopy (FM), and Xpert MTB/RIF. Using Xpert as the operational reference, ZN and FM exhibited overall sensitivities of 55.9% (89/159) and 68.5% (109/159), respectively. In paired sputum-only analyses (<i>n</i> = 446; sputum Xpert positives = 145), ZN and FM sensitivities were 60.0% (87/145) and 70.3% (102/145), respectively; sputum specificity was 100% for both methods. Xpert detected 31.2% (159/509) positive cases-78.7% more than ZN and 45.9% more than FM. Rifampicin resistance was identified in 5.03% (8/159) of Xpert-positive samples and was strongly associated with prior treatment (<i>P</i> < 0.001); RR-TB occurred in 66.7% (6/9) of retreatment cases vs 1.3% (2/150) of new cases. Xpert increased detection in paucibacillary and extrapulmonary specimens. These findings support expanded use of rapid molecular testing, but results should be interpreted cautiously because culture/speciation was not performed.IMPORTANCEThe spread of drug-resistant tuberculosis (TB) is a growing public health threat in Nepal. Using a rapid molecular test in Biratnagar, we simultaneously diagnosed TB and identified rifampicin resistance. We found rifampicin-resistant TB in >5% of Xpert-positive patients, higher than national averages for new cases, and a markedly elevated risk among previously treated patients. Rapid detection of resistance permits earlier initiation of appropriate therapy and can reduce onward transmission.

Authors

Institutions

Publication Details

Journal
Microbiology Spectrum
Published
2026-03-11
DOI
https://doi.org/10.1128/spectrum.02460-25
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative evaluation of sputum microscopy and Xpert MTB/RIF assay for tuberculosis detection and rifampicin resistance surveillance in Biratnagar, Nepal

Om Prakash Panta, Chandan Sah Kalwar, Akash Adhikari, Sujan Adhikari et al.
Microbiology Spectrum
Tuberculosis Research and Epidemiology
article

Comparative evaluation of sputum microscopy and Xpert MTB/RIF assay for tuberculosis detection and rifampicin resistance surveillance in Biratnagar, Nepal

Om Prakash Panta, Chandan Sah Kalwar, Akash Adhikari, Sujan Adhikari, Shristy Ojha, Swagat Khanal
article en

Abstract

Tuberculosis (TB) control in Nepal faces persistent challenges due to underdiagnosis and increasing drug resistance. This study assessed the diagnostic performance of the Xpert MTB/RIF assay compared with conventional smear microscopy and estimated the prevalence of rifampicin-resistant TB (RR-TB) in Biratnagar, a high-burden urban center. Between March and September 2023, 509 clinical specimens from TB suspects were analyzed by Ziehl-Neelsen (ZN) staining, fluorescence microscopy (FM), and Xpert MTB/RIF. Using Xpert as the operational reference, ZN and FM exhibited overall sensitivities of 55.9% (89/159) and 68.5% (109/159), respectively. In paired sputum-only analyses (<i>n</i> = 446; sputum Xpert positives = 145), ZN and FM sensitivities were 60.0% (87/145) and 70.3% (102/145), respectively; sputum specificity was 100% for both methods. Xpert detected 31.2% (159/509) positive cases-78.7% more than ZN and 45.9% more than FM. Rifampicin resistance was identified in 5.03% (8/159) of Xpert-positive samples and was strongly associated with prior treatment (<i>P</i> < 0.001); RR-TB occurred in 66.7% (6/9) of retreatment cases vs 1.3% (2/150) of new cases. Xpert increased detection in paucibacillary and extrapulmonary specimens. These findings support expanded use of rapid molecular testing, but results should be interpreted cautiously because culture/speciation was not performed.IMPORTANCEThe spread of drug-resistant tuberculosis (TB) is a growing public health threat in Nepal. Using a rapid molecular test in Biratnagar, we simultaneously diagnosed TB and identified rifampicin resistance. We found rifampicin-resistant TB in >5% of Xpert-positive patients, higher than national averages for new cases, and a markedly elevated risk among previously treated patients. Rapid detection of resistance permits earlier initiation of appropriate therapy and can reduce onward transmission.

Microbiology Spectrum
Central University of Technology (ZA), Sam Higginbottom Institute of Agriculture (IN), Agriculture and Forestry University (NP), Institute of Agriculture and Animal Science
Good health and well-being
Openalex Percentile: Top 27%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.